Merck Enters into a Clinical Collaboration with Hookipa to Evaluate Keytruda (pembrolizumab) + HB-200 as 1L Treatment of Advanced Head and Neck Cancers

Shots:

The companies collaborated to evaluate Hookipa’s HB-200 (arenaviral immunotherapeutic) + Merck’s Keytruda (anti-PD-1 therapy) in a P-II trial for patients with advanced HNSCC, based on an ongoing P-I/II trial of HB-200 for advanced HPV16+ cancers patients
HB-201 monothx. showed an ORR (18%), m-PFS (3.45mos.) in heavily pretreated head & neck cancer patients. Preliminary data on HB-201/HB-202 therapy showed a DCR (100%) & P-I data of HB-201 demonstrated a favorable safety profile
Hookipa is expected to start the P-II trial of HB-200 + Keytruda in 2022 with an anticipated result in Q4’21. Additionally, the company is also expected to initiate P-II expansion cohorts in Q1’22

Click here to read full press release/ article | Ref: Globenewswire | Image: Fierce Pharma